The AlphaLISA® immunoassay kit for human CXCL13 enables the quantitative determination of human C-X-C Motif Chemokine Ligand 13 in serum and cell culture media using a homogeneous AlphaLISA assay (no wash steps).
Item(s) added to cart.
For research use only. Not for use in diagnostic procedures.
Please enter valid quantity
Please log in to add favorites.
NULL OR EMPTY CART
AlphaLISA technology allows the detection of molecules of interest in buffer, cell culture media, serum and plasma in a highly sensitive, quantitative, reproducible and user-friendly mode. In an AlphaLISA assay, a Biotinylated Anti-Analyte Antibody binds to the Streptavidin-coated Alpha Donor beads, while another Anti-Analyte Antibody is conjugated to AlphaLISA Acceptor beads. In the presence of the analyte, the beads come into close proximity. The excitation of the Donor beads provokes the release of singlet oxygen molecules that triggers a cascade of energy transfer in the Acceptor beads, resulting in a sharp peak of light emission at 615 nm.
C-X-C Motif Chemokine Ligand 13 (CXCL13), also known as B lymphocyte chemoattractant (BLC) or B cell-attracting chemokine 1 (BCA-1), is a CXC chemokine that binds receptor CXCR5 and plays a role in promoting the migration of B lymphocytes. This protein ligand can be found in the liver, lymph nodes, spleen and is expressed by neutrophils, macrophages, dendritic cells and epithelial cells. Elevated levels of CXCL13 are expressed in tumors, specifically breast cancer patients with metastatic diseases. CXCL13 serves as a potential therapeutic target or diagnostic marker.
|Assay Target Class||Cytokine|
|Product Brand Name||AlphaLISA|
|Shipping Condition||Dry Ice|
|Unit Size||500 Assay Points|